<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756430</url>
  </required_header>
  <id_info>
    <org_study_id>125HT12001</org_study_id>
    <nct_id>NCT01756430</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus
      Carvedilol IR in Patients With Essential Hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In patients with Essential hypertension to evaluate the efficacy and safety of
           Carvedilol SR (32mg, 64mg) or Carvedilol IR (25mg QD, 25mg BID) during 8 weeks.

        -  This study is consist of placebo run-in period(2~4 weeks_single blind) and treatment
           period(8 weeks_double blind).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>After 4 and 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 4 weeks and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control Rate</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Sitting DBP&lt;90mmHg, Sitting SBP&lt;140mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Reduction of Sitting DBP≥10mmHg, Sitting SBP ≥20mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Carvedilol SR 32mg, 64mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol IR 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol SR 32mg, QD</intervention_name>
    <description>Carvedilol SR 32mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.</description>
    <arm_group_label>Carvedilol SR 32mg, 64mg</arm_group_label>
    <other_name>Dilatrend SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol SR 64mg, QD</intervention_name>
    <description>Carvedilol SR 64mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.</description>
    <arm_group_label>Carvedilol SR 32mg, 64mg</arm_group_label>
    <other_name>Dilatrend SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol IR 25mg, QD</intervention_name>
    <description>Carvedilol IR 25mg QD for 4 weeks
With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.</description>
    <arm_group_label>Carvedilol IR 25mg</arm_group_label>
    <other_name>Dilatrend IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol IR 25mg, BID</intervention_name>
    <description>Carvedilol IR 25mg BID for 4 weeks
With the others investigation product placebo 2 capsules QD for 4 weeks.</description>
    <arm_group_label>Carvedilol IR 25mg</arm_group_label>
    <other_name>Dilatrend IR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  at the screening visit(visit 1)

               -  antihypertensive drugs not taking: 90mmHg ≤ mean sitDBP ≤ 109mmHg and mean sitSBP
                  &lt; 180mmHg

               -  antihypertensive drugs taking: mean sitDBP ≤ 104mmHg and mean sitSBP &lt; 180mmHg

          -  at the randomization visit(visit 2): 90mmHg ≤ mean sitDBP ≤ 109mmHg and mean sitSBP &lt;
             180mmHg

          -  willing and able to provide written informed consent

        Exclusion Criteria:

          1. At Screening, difference in measured blood pressure of the selected arm(sitDBP ≥
             10mmHg or sitSBP ≥ 20mmHg)

          2. known or suspected secondary hypertension(ex. aortic coarctation, Primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)

          3. Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as
             defined by fasting glucosylated hemoglobin(HbA1c &gt; 9%)

          4. Corresponding to the following

               -  has severe heart disease(Heart failure NYHA functional class 3, 4)

               -  ischaemic heart diseases within 6 months (unstable angina or myocardial
                  infarction)

               -  myocardiopathy

               -  Cor pulmonale

               -  aortic stenosis , aortic valvular stenosis , mitral stenosis

               -  abnormality of the conduction system as 2nd degree AV block, Complete AV block,
                  Sick Sinus Syndrome, Sinus Block(In particular, pulse &lt;50beats / min)

               -  has heart attack with complication.

          5. has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6
             months

          6. has edema glottitis, allergic rhinitis, Respiratory diseases as Asthma, Chronic
             Obstructive Pulmonary Disease.

          7. Peripheral circulatory disturbance( ex. Raynaud syndrome, intermittent claudication)

          8. Fluid retention or overload to required intravenous inotropes.

          9. known severe or malignant retinopathy(retinal hemorrhage, visual disturbance, Retinal
             microaneurysms and so on within 6 months)

         10. defined by the following laboratory parameters:

               -  hepatic dysfunction(AST/ALT ≥ UNL X 3)

               -  renal dysfunction(serum creatinine ≥ UNL X 2)

         11. any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of investigational products(ex.
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,
             active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers
             need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such
             as pancreatitis, obstructions of the urinary tract or difficulty in voiding)

         12. history of drug or alcohol dependency within 6 months

         13. premenopausal women(last menstruation &lt; 12 months) not using adequate contraception,
             pregnant or breast-feeding

         14. chronic inflammatory status need to treatment

         15. known hypersensitivity related to carvedilol

         16. history of malignancy including leukemia and lymphoma within the past 5 years

         17. administration of other study drugs within 28 days prior to the first IP
             administration

         18. in investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soon Kill Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hanyang Universitiy Guri Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Hyun Ihm</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea Bucheon St.Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hong Haek</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea, Seoul St. Vincent's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Bae Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Woon Jeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHIC Ilsan hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Wook Nam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University, Donsan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Ju Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Su Hyon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soon Chun Hyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Jin Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sejong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuck Moon Kwon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geu Ru Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Su Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji-Hyun Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jesus hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Keun Ahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Ho Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University Seoul Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hanyang Universitiy Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carvedilol SR</keyword>
  <keyword>Carvedilol IR</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Essential Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

